Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.
Billions of dollars in potential awards, a new map for antitrust litigation, and what many say is a likely spot on the Supreme Court docket; Empagran v. F. Hoffman-LaRoche has it all. What could it mean for U.S. pharmaceutical (and other) companies? “Corporations in this country and all over the world are really scared of this,” says Paul Gallagher, a Washington D.C.-based Cohen, Milstein, Hausfeld & Toll partner who serves as lead plaintiffs counsel in the case.
A class action filed by foreign vitamin buyers, the suit is the latest round in the already epic litigation over vitamin price fixing. The cases stem from a Department of Justice criminal investigation that began in the mid-1990s and have yielded more than $1 billion in fines against a cartel of multinational pharmaceutical giants.
The DOJ's Criminal Division issued three declinations since the issuance of the revised CEP a year ago. Review of these cases gives insight into DOJ's implementation of the new policy in practice.
The parameters set forth in the DOJ's memorandum have implications not only for the government's evaluation of compliance programs in the context of criminal charging decisions, but also for how defense counsel structure their conference-room advocacy seeking declinations or lesser sanctions in both criminal and civil investigations.
This article discusses the practical and policy reasons for the use of DPAs and NPAs in white-collar criminal investigations, and considers the NDAA's new reporting provision and its relationship with other efforts to enhance transparency in DOJ decision-making.
There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.
This article explores legal developments over the past year that may impact compliance officer personal liability.